2009 Annual Report Introduction · About DSV - Global Transport and Logistics

Total Page:16

File Type:pdf, Size:1020Kb

2009 Annual Report Introduction · About DSV - Global Transport and Logistics 2009 Annual Report introducTION · ABOUT DSV - Global Transport AND LogisticS About DSV Global Transport and Logistics DSV is a global supplier of transport and logistics solutions. The Group has companies in more than 60 countries all over the world. Together with our partners and agents, our staff of around 21,300 employees offer local distribution, European road transport, air and seafreight within and between the largest continents, and professional overall solutions in more than 110 countries. DSV ROAD transports all kinds of freight by road all over Europe in a quick, efficient, REVENUE (DKK) flexible and environmentally friendly manner – creating good connections to the rest of MILLION the world. 36,085 OPERATING PROFIT (DKK)* DSV AIR & SEA is an international freight forwarder which plans and effects the forwarding of all kinds of air and seafreight in a quick, efficient, safe and environmentally 1,703 MILLION friendly manner within and between continents, whether on short-sea routes in Europe or intra-Asia routes, always combining the means of transports when most appropriate. NUMBER OF EMPLOYEES: DSV SOLUTIONS designs and offers logistics solutions across the full supply chain from 21,280 design through freight management, customs clearance, warehousing and distribution to information management and e-business support. * before special items (EBITA) 2 2009 DSV annual report cONTENTS · introducTION Road REVENUE (DKK) introducTION DKK 18,390 MILLION About DSV – Global Transport and Logistics 2 OPERATING PROFIT* DKK 597 MILLION A stronger and more complete DSV 4 NUMBER OF EMPLOYEES Financial highlights 7 9,858 Financial targets and capital structure 8 Air & Sea REVENUE (DKK) 14,062 MILLION OPERATING PROFIT (DKK)* MANAGEMENT’S REVIEW 955 MILLION Financial review 9 NUMBER OF EMPLOYEES 5,925 Road – Divisional review 14 Air & Sea – Divisional review 18 REVENUE (DKK) Solutions Solutions – Divisional review 22 5,788 MILLION OPERATING PROFIT (DKK)* Shareholder information 26 196 MILLION Corporate governance 28 NUMBER OF EMPLOYEES 5,497 Risk factors 28 * before special items (EBITA) Corporate governance statement 29 Corporate social responsibility statement 30 Execcutive and Supervisoty Boards 33 ENDORMENTS Management’s statement 34 Independent auditors’ report 35 Consolidated fINANcIAL statementS Income statement 36 Statement of comprehensive income 36 Balance sheet 37 Cash flow statement 38 Statement of changes in equity 39 Notes 40 Group Structure 71 DSV history 74 Annual REport ParenT CD containing 2009 Annual Report of Parent 75 Countries in wich DSV has its own companies 3 2009 DSV annual report introducTION · A stronger AND more complete DSV DSV A/S cEO’s report A stronger and more complete DSV In many ways, 2009 was an extraordinary year for DSV DSV Air & Sea the most profitable in which the integration of ABX LOGISTICS (ABX) and the In our Air & Sea Division we saw an unprecedented, rapid crisis in the world economy impacted on our finacial results decline in both container and airfreight rates, but we ex- and our company in general. perienced the conclusion of this effect during the summer period. This was primarily caused by capacity in both sea The main reasons were volatility in freight volumes, freight and airfreight being taken out of the market. rates, exchange rates and fuel prices to a degree never experienced before, but as a consequence of our asset During the year, we expanded our contribution ratio to a light business model combined with an aggressive cost level never experienced before in DSV. This was caused by cutting programme, we achieved results that we consider the generally lower rate levels, but to a large degree also by satisfactory. the fact that we managed to maximise our buying power in the market. Asset-light strategy is the way forward The year started relatively weak with a significant drop in Since the summer period, we have experienced rapidly international trade, partly because our customers ran down increasing rate levels. We believe that rate levels will show their inventories, which had a negative impact on both a moderately upward trend in 2010. In all likelihood this will revenue and contribution margin. also lead to a somewhat lower contribution ratio in 2010. In 2009, we cherished more than ever before our flexible For the second year running, the Air & Sea Division was business model without fixed capacity in the form of trucks, the most profitable business unit of DSV. We welcome this ships and aeroplanes. We therefore successfully managed development and we believe that growth rates for the to keep our exposure to operational fixed costs at a very markets in which the Division operates will exceed growth low level, and the lesson learned in 2009 was that the DSV rates in other parts of the world. strategy of being asset light is the way forward. 4 2009 DSV annual report A stronger AND more complete DSV · introducTION DSV Road trimmed for 2010 The Road Division also experienced a slow start of the We therefore success- year with volumes dropping as much as 20% in certain geographical areas. We experienced large overcapacity of fully managed to keep hauliers in Europe, which meant that lower freight rates in the market could be offset by lower supplier costs. our exposure to operational We started the year with unsatisfactory results in three of Europe’s most important countries for DSV: Germany, fixed costs at a very low France and Spain. During the year, we were forced to make changes in senior management positions in all three coun- level, and the lesson learned tries, and we are now more comfortable with the situation than ever before. The momentum seems to have changed, in 2009 was that the DSV and we feel a new sense of optimism, leaving us to believe that the weak performance in 2009 will be outweighed by better results in 2010. strategy of being asset light We are of the opinion that we have a very unique platform is the way forward. in Europe with a full and dense network of DSV branches and good collaboration with our subcontractors. We aim to benefit from this strategic advantage in 2010. Stronger global sales organisation Despite the general decline in international transport vol- Satisfactory contribution from Solutions umes, we managed to gain market shares in 2009 in DSV’s The Solutions Division delivered overall satisfactory results main markets, particularly within the Road Division and for in 2009. It is the least asset-light of our three Divisions. seafreight. The cross-selling opportunities between the Divisions are extensive and will be enhanced even further This Division was also hit by the consequences of the in the future enabling us to gain further market shares. We economic crisis and the de-stocking effect experienced recently substantially enlarged our unit dealing with global in 2009, leaving more idle space in our warehouses than accounts, and we have appointed one of our most experi- previously. enced country managers as Chief Commercial Officer for all three DSV Divisions. The reason for this is that DSV has Still, we surpassed previous year’s performance in certain now reached a size that makes it possible to attract more countries, and the Solutions Division still delivers added large multinational customers, which several new initiatives value, i.a. by very sophisticated operations developed in all planned for 2010 will hopefully show. countries in Europe in close cooperation with customers and the two other Divisions. Reduced cost base During 2009, we systematically reduced our cost base A complete and strong DSV and were successful in achieving operational leverage and The uncertainty about future developments in international increasing productivity per employee. Since the acquisition trade is fairly high, but we still feel that the DSV Group is of ABX at the end of 2008, we have managed to reduce more complete and in better shape than ever before. the total number of employees of DSV by approximately 20%. Even though it was a tough and very difficult task Through the acquisition of ABX in 2008, we achieved and we had to say goodbye to many loyal and experienced a better balance between the three Divisions of DSV, employees, we had to adjust our cost base to the new and enabling us to offer a true one-stop shopping experience lower activity level. to our customers. We are now a truly global player in the transport market capable of offering services to all parts of The cost of labour is the highest cost component of DSV, the world, to a large degree even within our own network and consequently a substantial reduction of employees was of offices. necessary. We have the clear impression that we are ready for a potential rebound in world trade and that the first increase in activity will be handled within the existing low cost environment. 5 2009 DSV annual report introducTION · A stronger AND more complete DSV Responsibility and environment With the continued In 2009, we experienced an increased focus from both customers and shareholders on corporate social responsibil- support of our ity matters. As a consequence, we joined the United Nations Global Compact initiative, and we are now in the process of describing and implementing the relevant policies. Several of loyal customers and these initiatives have had our attention for many years, but dedicated employees will now become part of a more structured process. DSV’s impact on climate and environment caused by we are ready to meet greenhouse gases, particulate matter, etc., has been closely measured for years and we have further expanded our the challenges ahead. work in this field so that we can now indentify the overall carbon footprint of DSV. During 2010, we will pursue a strategy which will involve a clear ambition of reducing our carbon footprint.
Recommended publications
  • Aktienyt Novozymes
    Aktienyt Novozymes Hold Udfordrende markeder dæmper salgsvæksten Uændret Hold-anbefaling siden 20/04/2016 Vi fastholder vores Hold-anbefaling på Novozymes Dagens regnskab er lidt svagere, end vi havde ventet. Hård priskonkurrence i ’Bioenergi’ og økonomisk Analysedato: 10/08/2016 pressede kunder i ’Landbrug og Foder’ dæmper Novozymes’ salgsvækst. Pris- fastsættelsen af Novozymes-aktien afspejler efter vores vurdering Novozymes’ Aktuel kurs kl. 12:11: kortsigtede forretningsmuligheder. 295,00 DKK Salgsvæksten skuffer i årets 2. kvartal Omsætningen på 3.429 mio. kr. i 2. kvartal 2016 er 3,3% dårligere end vores estimat (-3,5% i Begivenhed: forhold til markedsforventningen). Resultatet af primær drift på 961 mio. kr. i 2. kvartal 2016 er 2,9% under vores estimat (-2,6% i forhold til markedsforventningen). I forhold til vores for- 2. kvartalsregnskab ventning er det specielt salget i divisionerne ’Bioenergi’ og ’Landbrug og Foder’, der viser en svagere end ventet udvikling i 2. kvartal. Novozymes justerer salgsprognosen for 2016 i lokal Seneste analyse: valuta. Selskabet venter nu en salgsvækst i lokal valuta på 2-4% i 2016 mod tidligere 3-5%. 05/08/16 – Vækst i ’Vaskemid- Novozymes forventer, at salgsvæksten i danske kroner forbliver uændret på 1-3% i 2016. ler’ – Tilbagegang i ’Bioenergi’ Salgsvæksten i ’Vaskemidler’ overgår vores forventning Den organiske salgsvækst i divisionen ’Vaskemidler’ på 4% i 2. kvartal er lidt bedre end vo- res estimat på 3%. Vi hæfter hos ved, at salget vokser i Asien drevet af øget penetration af Kalender: enzymer i flydende vaskemidler. Yderligere noterer vi os, at den positive salgsudvikling er 26/10/16 – 3.
    [Show full text]
  • Aktiekommentar Novozymes
    Aktiekommentar Novozymes Sælg Novozymes står på dørtærsklen til et kommercielt Uændret gennembrud i 2G-biobrændstofindustrien Aktuel kurs: 216,30 DKK Begivenhed: Vi fastholder Sælg-anbefalingen på Novozymes. Værdiansættelsen af Novozy- mes-aktien indregner efter vores vurdering allerede store forventninger til Novo- zymes’ fremtidige salg og indtjening fra 2G-biobrændstofenzymer. 2G-industrien Optakt til kapitalmar- er dog i sin spæde opstartsfase. Der er fortsat stor usikkerhed forbundet med kedsdag hvilke teknologiske løsninger, der vil blive markedsledende. Vi forventer dog, at Novozymes vil få en betydelig markedsposition som leverandør til 2G-industrien. Baggrund: Novozymes afholder kapitalmarkedsdag den 31. oktober 2013. Det overordnende tema for dagen er anden generations biobrændstof (2G) og mulighederne for Novozymes i denne indu- stri. Verdens første kommercielle 2G-bioethanolproduktion er for nylig startet op i Cresentino i Italien med Novozymes som enzymleverandør. Produktionsanlægget er opført af italienske Beta Renewables, som Novozymes ejer 10% af. Konklusion: På kapitalmarkedsdagen vil vi have fokus på følgende punkter: - Produktionsøkonomien på det italienske 2G-anlæg – er det kommercielt konkurren- cedygtigt? - Statusopdatering på Novozymes’ globale partnerskabsaftaler – tidshorisont for kom- merciel 2G-produktion på forskellige markeder - Novozymes/Beta Renewables styrker i forhold til konkurrerende teknologier Vi forventer, at Novozymes i 2015 kan opnå et globalt enzymsalg til 2G- biobrændstofsproduktion på 213 mio. kr. stigende til 2.166 mio. kr. i 2020. Vi forventer, at Ki- na og Brasilien vil agere vækstmotor for udviklingen af 2G-industrien, mens vi først forventer, at udviklingen i USA kommer op i tempo efter 2015. Det er efter vores vurdering helt centralt, at Novozymes har indgået et samarbejde med itali- enske Beta Renewables.
    [Show full text]
  • Annual Report 2019 Sydbank Group Preface
    Annual Report 2019 Sydbank Group Preface 4 SYDBANK / 2019 Annual Report 2019 characterised by growth in total credit intermediation and historically high remortgaging activity Sydbank’s 2019 financial statements show a profit before tax of DKK 1,081m compared to DKK 1,420m in 2018. The decrease of DKK 339m is mainly attributable to a drop in total income of DKK 210m and a change in non-re- 2019 highlights curring items of DKK 109m. Profit before tax equals a return of 9.7% p.a. on • A 5% decrease in total income average equity. • A 2% rise in costs (core earnings) • A reversal of DKK 97m in impairment charges Profit for the year after tax represents DKK 853m against DKK 1,161m in • A drop in core earnings of DKK 296m to DKK 1,193m 2018, equal to a return on average equity of 7.5%. At the beginning of 2019 • Negative investment portfolio earnings of DKK 61m profit after tax was projected to be in the range of DKK 800-1,100m. • Bank loans and advances of DKK 60.6bn CEO Karen Frøsig comments on the year’s result and the current strategy: • Total credit intermediation of DKK 145.1bn - It is good news that a sizeable improvement in total credit intermediation of • Deposits of DKK 84.3bn almost DKK 3bn has been recorded and that credit quality is still so good that • A capital ratio of 22.9%, including a CET1 ratio of 17.8% we were able to reverse impairment charges amounting to almost DKK 100m • A proposed dividend of DKK 5.70 per share in 2019.
    [Show full text]
  • Annual Report 2011 3) the Calculation Is Based on a Share Denomination of DKK 5
    Financial highlights Group 2011 2010 2009 2008 2007 2011 2011 DKKm DKKm DKKm DKKm DKKm EURm1 USDm2 Revenue 16,007 14,765 13,747 11,572 11,171 2,148 2,987 Research and development costs 3,320 3,045 3,196 2,990 2,193 446 620 Operating profit before depreciation and amortisation (EBITDA) 4,628 4,393 3,728 3,418 3,611 621 864 Profit from operations (EBIT) 3,393 3,357 2,858 2,354 2,689 455 633 Net financials (96) (68) (192) (28) 65 (13) (18) Profit for the year 2,282 2,466 2,007 1,663 1,881 306 426 Total assets 20,534 18,005 17,127 12,526 12,230 2,762 3,574 Equity 12,776 11,122 8,803 7,511 7,089 1,719 2,224 Cash flows from operating and investing activities 929 2,462 (2,040) 2,193 1,610 125 173 Investments in property, plant and equipment, gross 419 383 258 229 474 56 73 % % % % % % % EBITDA margin 28.9 29.8 27.1 29.5 32.3 28.9 28.9 EBIT margin 21.2 22.7 20.8 20.3 24.1 21.2 21.2 Return on capital employed 25.3 27.6 28.0 30.0 34.6 25.3 25.3 Return on equity 19.1 24.8 24.6 22.8 27.3 19.1 19.1 Research and development ratio 20.7 20.6 23.2 25.8 19.6 20.7 20.7 Solvency ratio 62.2 61.8 51.4 60.0 58.0 62.2 62.2 Capital turnover 78.0 82.0 80.3 92.4 91.3 78.0 78.0 Effective tax rate 30.8 25.0 24.7 27.1 29.6 30.8 30.8 DKK DKK DKK DKK DKK EUR1 USD2 Earnings per share (EPS)3 11.63 12.57 10.24 8.45 9.18 1.56 2.17 Diluted earnings per share (DEPS)3 11.63 12.57 10.24 8.45 9.17 1.56 2.17 Proposed dividend per share3 3.49 3.77 3.07 2.30 2.56 0.47 0.65 Cash flow per share3 18.48 16.65 15.47 14.12 13.18 2.48 3.45 Net asset value per share3 65.14 56.71 44.89
    [Show full text]
  • EMTN-2020-Prospectus.Pdf
    Prospectus JYSKE BANK A/S (incorporated as a public limited company in Denmark) U.S.$8,000,000,000 Euro Medium Term Note Programme On 22 December 1997, the Issuer (as defined below) entered into a U.S.$1,000,000,000 Euro Medium Term Note Programme (the “Programme”). This document supersedes the Prospectus dated 11 June 2019 and any previous Prospectus and/or Offering Circular. Any Notes (as defined below) issued under the Programme on or after the date of this Prospectus are issued subject to the provisions described herein. This Prospectus does not affect any Notes issued before the date of this Prospectus. Under the Programme, Jyske Bank A/S (the “Issuer”, “Jyske Bank” or the “Bank”) may from time to time issue notes (the ”Notes”), which may be (i) preferred senior notes (“Preferred Senior Notes”), (ii) non-preferred senior notes (“Non-Preferred Senior Notes”), (iii) subordinated and, on issue, constituting Tier 2 Capital (as defined in the Terms and Conditions of the Notes) (“Subordinated Notes”) or (iv) subordinated and, on issue, constituting Additional Tier 1 Capital (as defined in the Terms and Conditions of the Notes) (“Additional Tier 1 Capital Notes”) as indicated in the applicable Final Terms (as defined below). Notes may be denominated in any currency (including euro) agreed between the Issuer and the relevant Dealer (as defined below). The maximum aggregate principal amount of all Notes from time to time outstanding under the Programme will not exceed U.S.$8,000,000,000 (or its equivalent in other currencies calculated as described herein), subject to any increase as described herein.
    [Show full text]
  • Aktieanalyse GN Store Nord
    AktieAnalyse GN Store Nord Hold Amerikanske orkaner giver modvind til GN Hea- Uændret Hold-anbefaling siden 09/05/2017 ring Analysedato: 02/11/2017 Vi fastholder Hold-anbefalingen på GN Store Nord. GN Audio leverer som ven- tet rigtige stærke resultater i 3. kvartal. Til gengæld hakker salgsvækstmotoren i GN Hearing en smule i årets 3. kvartal. Værdiansættelsen af GN Store Nord- Aktuel kurs kl. 12:54 aktien indregner efter vores vurdering allerede i store træk GN Store Nords 203,70 DKK vækstmuligheder på den korte bane. Begivenhed: 3. kvartalsregnskabet er stort set på linje med vores forventning Omsætningen på 2.282 mio. kr. i 3. kvartal 2017 er 1,8% lavere end vores estimat (-0,9% i 3. kvartalsregnskab forhold til markedsforventningen). Resultat af primær drift på 371 mio. kr. er 0,9% dårligere end vores estimat. I forhold til vores indtjeningsestimat er det GN Hearing, der ikke kan indfri Seneste analyse: vores forventninger i 3. kvartal. GN Store Nord løfter salgsprognosen i GN Audio i forbindel- se med 3. kvartalsregnskabet, så GN Audio nu forventer en organisk salgsvækst på ’mere 30/10/17 – GN Audio vil løfte end 7%’ mod tidligere ’mere end 6%’. Vi forventer, at GN Audio meget komfortabelt kan salgsprognosen i 3. kvartals- indfri den nye salgsprognose, som i vores øjne fortsat ser lidt konservativ ud. regnskabet Salgsvæksten i GN Hearing når ikke vores forventning i 3. kvartal Omsætningen i GN Hearing er 2,3% under vores estimat i 3. kvartal. GN Hearing realiserer Kalender: en organisk salgsvækst på 6% i 3. kvartal, hvilket er under vores estimat på 8% organisk salgsvækst.
    [Show full text]
  • Aktienyt Novozymes
    Aktienyt Novozymes Hold To cylindre i salgsvækstmotoren sætter ud Uændret Vi fastholder Hold-anbefalingen på Novozymes. Dagens regnskab byder på en Aktuel kurs: overraskende nedjustering af den organiske salgsvækst drevet af udfordringer inden for vaskemidler og bioenergi. Vi forventer ikke, at Novozymes vil være i 321,1 DKK stand til at løse udfordringerne på den korte bane. Begivenhed: Salgsvæksten skuffer markant i 2. kvartal Omsætningen på 3.449 mio. kr. i 2. kvartal 2015 er 5,2 % dårligere end vores estimat (-6,1% 2. kvartalsregnskab ift. markedsforventningerne). Resultatet af primær drift på 930 mio. kr. i 2. kvartal 2015 er 4,7% dårligere, end vi havde forventet (-6,3% ift. markedsforventningerne). Det skal dog bemærkes, at driftsresultatet i 2. kvartal er negativt påvirket af en nedskrivning på 50 mio. kr. Seneste analyse: relateret til Novozymes’ farmaceutiske forretning. Når der ses bort fra nedskrivningen er 17/04/15 – Aktieudsyn – Min- overskudsgraden i 2. kvartal på 28,4%, hvilket er markant over vores estimat på 26,8%. No- dre valuta-drevet nedjustering vozymes nedjusterer salgsprognosen for 2015. Novozymes forventer nu, at salget vil vokse på vej 13-16% i danske kroner i 2015 mod tidligere 16-18%. I lokal valuta forventer Novozymes, at salget vil vokse med 4-7% mod tidligere 7-9%. Den stærke udvikling i indtjeningen i årets første seks måneder betyder, at Novozymes fastholder indtjeningsprognosen for 2015 på trods af den svagere salgsudvikling. Kalender: 22/10/15 – 3. kvartalsregnskab Hård konkurrence bland nordamerikanske vaskemiddelproducenter skaber udfordringer 19/01/16 – Årsregnskab 2015 Omsætningen fra vaskemiddelenzymer er 2% under vores estimat.
    [Show full text]
  • 2018 Annual Report Sydbank Group Preface
    2018 Annual Report Sydbank Group Preface Highest return on equity among SIFI banks in Denmark. All Blue growth objectives have been met Sydbank’s 2018 financial statements show a profit before tax growth in lending. The result achieved in 2018 ensures a high of DKK 1,420m compared with DKK 1,956m in 2017. The dividend per share as well as the possibility of launching a new decrease of DKK 536m is primarily attributable to a decline in share buyback programme of DKK 250m. After a total distribu- total income of DKK 311m and a drop in investment portfolio tion of DKK 840m, the Bank will continue to be well capitalised. earnings of DKK 309m. Profit before tax equals a return of 2018 highlights 12.5% p.a. on average equity. • A 7% decrease in total income Profit for the year after tax represents DKK 1,156m against • A 3% rise in costs (core earnings) DKK 1,531m in 2017, equal to a return on average equity of • A reversal of DKK 122m in impairment charges 10.2%. At the beginning of 2018 profit after tax was projected • A drop in core earnings of DKK 325m to DKK1,489m to be in the region of DKK 1,200-1,400m. • Negative investment portfolio earnings of DKK 127m • Bank loans and advances of DKK 61.0bn CEO Karen Frøsig comments on the year’s result: • Deposits of DKK 86.3bn - The banking environment has become significantly more chal- • A capital ratio of 22.4%, including a Common Equity Tier 1 lenging.
    [Show full text]
  • Important Notice the Depository Trust Company
    Important Notice The Depository Trust Company B #: 3489-16 Date: June 20, 2016 To: All Participants Category: Dividends From: International Services Attention: Operations, Reorg & Dividend Managers, Partners & Cashiers DENMARK ADR MARKET ANNOUNCEMENT ISSUE CUSIP A.P. MOLLER - MAERSK 00202F102 CARLSBERG 142795202 CHR. HANSEN 12545M207 COLOPLAST A/S 19624Y101 Subject: DSV 26251A108 FLSMIDTH & CO A/S 343793105 GN STORE NORD 3621ME105 NOVOZYMES A/S 670108109 PANDORA 698341104 SYDBANK 87124G102 VESTAS WIND SYSTEMS A/S 925458101 Effective as of September 13, 2016 Participants can use DTC’s Corporate Actions Web (CA Web) service to certify all or a portion of their position entitled to the applicable withholding tax rate. Participants are urged to consult TaxInfo respectively before certifying their instructions over the CA Web. Important: Prior to certifying tax withholding instructions, participants are urged to read, understand and comply with the information in the Legal Conditions category found on TaxInfo on the CA Web. Questions regarding this Important Notice may be directed to GlobeTax 212-747-9100. DTCC offers enhanced access to all important notices via a Web-based subscription service. The notification system leverages RSS Newsfeeds, providing significant benefits including real-time updates and customizable delivery. To learn more and to set up your own DTCC RSS alerts, visit http://www.dtcc.com/subscription_form.php. Non-Confidential 1 DTCC Public (White) Important Legal Information: The Depository Trust Company (“DTC”) does not represent or warrant the accuracy, adequacy, timeliness, completeness or fitness for any particular purpose of the information contained in this communication, which is based in part on information obtained from third parties and not independently verified by DTC and which is provided as is.
    [Show full text]
  • Aktieanalyse Coloplast
    AktieAnalyse Coloplast Sælg For positive indtjeningsscenarier indregnet i Co- Nedjusteret Fra Hold-anbefaling (siden 29/01/2014) loplast-aktien – vi sænker til Sælg Analysedato: 04/05/2017 Vi sænker vores anbefaling på Coloplast til ’Sælg’ (fra ’Hold’). Regnskabet for 2. kvartal er lidt svagere end ventet. Coloplast-aktien afspejler efter vores vur- dering et meget positivt indtjeningsscenarie de kommende år. Vi ser risiko for, Aktuel kurs kl. 11:13: at Coloplast ikke fuldt ud kan indfri de høje markedsforventninger. Set i det lys ser værdiansættelsen af Coloplast anstrengt ud. 551,50 DKK Regnskabet er lidt dårligere end ventet Begivenhed: Coloplast opnår en samlet organisk omsætningsvækst på 7% i 2. kvartal, hvilket er 1%- point dårligere end vores estimat og markedsestimaterne. Opkøbet af den amerikanske di- 2. kvartalsregnskab stributør Comfort Medical bidrager med 2%-point til væksten, mens en negativ valutaeffekt trækker i modsatte retning, så omsætningen lander på 3.881 mio. kr. Det er 1% dårligere end vores estimat (på linje med markedsestimaterne). Resultatet af primær drift (EBIT) vok- Seneste analyse: ser 7% i forhold til 2. kvartal 2015/16 til 1.246 mio. kr., hvilket er 2% dårligere end vores 28/04/17 – Udsigt til øget estimat (-1% ift. markedsestimaterne). Coloplast fastholder prognosen for helåret i både lo- væksttempo i 2. kvartal kal valuta og i danske kroner. Desuden annoncerer Coloplast ekstraordinært udbytte på 4,50 kr. pr. aktie. Udviklingen i ’hud- og sårpleje’ skuffer i 2. kvartal Kalender: Væksten inden for ’Stomi’ er som i de foregående kvartaler drevet af Sensura- 16/08/17 – 3. kvartalsregnskab produktporteføljen og tilbehørsprodukterne Brava.
    [Show full text]
  • Aktieanalyse Novozymes
    AktieAnalyse Novozymes Køb Novozymes lægger godt fra land i 2017 Uændret Købsanbefaling siden 18/01/2017 Vi fastholder vores Købsanbefaling på Novozymes efter dagens regnskab. No- vozymes leverer efter vores vurdering en rigtig god start på 2017. 1. kvartals- Analysedato: 26/04/2017 regnskabet er med til understøtte vores forventning om, at Novozymes kan lan- de i den øvre ende af både salgs- og indtjeningsprognosen for 2017. Aktuel kurs kl. 11:37 2017 starter med en positiv overraskelse 303,30 DKK Omsætningen på 3.740 mio. kr. i 1. kvartal 2017 er 1,0% bedre end vores estimat (+1,2% ift. markedets forventning). Vi finder det meget positivt, at kunderne i stigende omfang viser in- Begivenhed: teresse for Novozymes’ seneste produktlanceringer. Resultatet af primær drift på lander på 1.010 mio. kr. i 1. kvartal, hvilket er 1,6% dårligere end vores estimat (+0,4% i forhold til 1. kvartalsregnskab markedsforventningen). Vi noterer os dog, at engangsomkostninger på ca. 70 mio. kr. sæn- ker indtjeningsevnen i 1. kvartal. Renset for engangsomkostningerne viser Novozymes fort- Seneste analyse: sat en god evne til at løfte selskabets overskudsgrad, der lander på 29% (ekskl. engangs- 21/04/17 – Salgsvækstmoto- omkostninger). Det er en forbedring på 1%-point på overskudsgraden i forhold til 1. kvartal ren går i tomgang i 1. kvartal 2016. Genstridigt snavs samler sig i horisonten for ’Vaskemidler’ ’Vaskemidler’ leverer en organisk vækst på 1% i 1. kvartal 2017, hvilket er en spids dårligere Kalender: end vores estimat på 2% organisk salgsvækst. Vi hæfter os specielt ved, at Novozymes kan 11/08/17 – 2.
    [Show full text]
  • Aktieanalyse H. Lundbeck
    AktieAnalyse H. Lundbeck Køb Indtjeningsgenrejsningen fortsætter i 2017 Uændret Købsanbefaling siden 10/02/2016 Vi fastholder ’Køb’ på Lundbeck. Lundbeck leverer et regnskab, hvor udviklin- gen i 4. kvartal er bedre end ventet. Vi vurderer, at en fortsat solid salgsvækst Analysedato: 08/02/2017 og effekterne af Lundbecks besparelsesprogram vil sikre selskabet en gradvist stigende indtjening, som ikke er afspejlet i den nuværende aktiekurs. Aktuel kurs kl. 14:34: 2017-prognosen er bredt formuleret Omsætningen stiger 12% og lander på 4.165 mio. kr. i 3. kvartal. Det er på linje med vores 287,00 DKK estimat (+2% ift. markedsforventningerne). Resultatet af primær drift (EBIT) er forbedret med 980 mio. kr. i kvartalet i forhold til 4. kvartal 2015 (korrigeret for nedskrivninger i 4. Begivenhed: kvartal 2015). EBIT på 751 mio. kr. i kvartalet er på linje med vores estimat (+11% ift. mar- kedsestimaterne). Lundbeck annoncerer en 2017-prognose om en omsætning i intervallet Årsregnskab 2016 16,3-17,1 mia. kr. og EBIT i intervallet 3,4-3,8 mia. kr. Markedsestimaterne for 2017 ligger i den øvre ende af Lundbecks prognoseinterval. Lundbecks stærke pengestrømsgenerering betyder, at selskabet annoncerer et udbytte på 2,45 kr. pr. aktie svarende til 40% af netto- resultatet. Lundbeck meddeler hertil, at selskabet agter at udbetale 60-80% af nettoresulta- Seneste analyse: tet i 2017 og fremefter. 03/02/17 – Udsigt til stærk årsafslutning for Lundbeck Ældre midler klarer sig bedre end frygtet – nye midler lidt svagere end ventet Vi hæfter os ved et bedre end frygtet salg af de af Lundbecks midler, der er løbet af patent.
    [Show full text]